DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

Name	Symbol	Market	Type
Davis Select US Equity	AMEX:DUSA	AMEX	Exchange Traded Fund

Name

Symbol

Market

Type

Davis Select US Equity

AMEX:DUSA

AMEX

Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.38	0.90%	42.74	42.88	42.24	42.37	33,753	21:25:00

Price Change

% Change

Price

High Price

Low Price

Open Price

Traded

Last Trade

0.38

0.90%

42.74

42.88

42.24

42.37

33,753

21:25:00

DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

02/09/2009 1:30pm

PR Newswire (US)

Davis Select US Equity (AMEX:DUSA)
Historical Stock Chart

From Dec 2019 to Dec 2024

Click Here for more Davis Select US Equity Charts.

WILMINGTON, Mass., Sept. 2 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA), a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9, 2009 at 4:30 p.m. EDT at The New York Palace Hotel in New York. Interested investors can access the live audio webcast of the presentation at http://www.dusapharma.com/. An archived version of the presentation will be available on the DUSA website for 90 days following the presentation. (Logo: http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO ) About DUSA Pharmaceuticals DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach . DUSA is researching the use of Levulan PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplanth recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at http://www.dusapharma.com/. http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO DATASOURCE: DUSA Pharmaceuticals, Inc. CONTACT: Chad Rubin, Investor Relations Contact, The Trout Group LLC, +1-646-378-2947, for DUSA Pharmaceuticals, Inc. Web Site: http://www.dusapharma.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

DUSA Davis Select US Equity